热门资讯> 正文
Kyverna Therapeutics任命Marc Grasso为首席财务官
2025-06-30 21:32
- Kyverna Therapeutics (NASDAQ:KYTX) announced on Monday the appointment of Marc Grasso as its chief financial officer (CFO), effective today.
- Most recently, Grasso served as CFO of Alector, a clinical-stage biotechnology company focused on neurodegenerative diseases, where he oversaw Financial Planning and Analysis, Investor Relations, Accounting, Information Technology and Facilities. Prior to Alector, Grasso held the position of CFO and chief business officer of Kura Oncology.
- In connection with the appointment of Grasso as CFO, on June 30, 2025, Kyverna will grant Grasso an option to purchase 450,000 shares of its common stock.
- KYTX +3.04% premarket to $3.38.
- Source: Press Release
More on Kyverna Therapeutics
- Seeking Alpha’s Quant Rating on Kyverna Therapeutics
- Historical earnings data for Kyverna Therapeutics
- Financial information for Kyverna Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
